◆英語タイトル:Regeneron Pharmaceuticals Inc (REGN) - Product Pipeline Analysis, 2020 Update
◆商品コード:GDME81628PD
◆発行会社(調査会社):
GlobalData
◆発行日:2021年1月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Regeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab, Veloci-Bi and other related technologies. The company operates manufacturing facilities in Rensselaer, New York and Limerick, Ireland. It also works in collaboration with strategic partners to develop, manufacture and commercialize its products. It sells its products to specialty pharmacies and distributors. The company and its subsidiaries operate in the US, Bermuda, the Netherlands, Ireland, Spain and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Regeneron Pharmaceuticals Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
List of Tables
List of Figures
Regeneron Pharmaceuticals Inc Company Overview
Regeneron Pharmaceuticals Inc Company Snapshot
Regeneron Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview
Regeneron Pharmaceuticals Inc – Pipeline Analysis Overview
Business Description
Regeneron Pharmaceuticals Inc – Key Facts
Regeneron Pharmaceuticals Inc – Major Products and Services
Regeneron Pharmaceuticals Inc Pipeline Products by Development Stage
Regeneron Pharmaceuticals Inc Pipeline Products Overview
DUPIXENT Pre-filled Syringe
DUPIXENT Pre-filled Syringe Product Overview
DUPIXENT Pre-filled Syringe – Adolescents
DUPIXENT Pre-filled Syringe – Adolescents Product Overview
DUPIXENT Pre-filled Syringe – Pediatric Atopic Dermatitis (6 mo-5 yr)
DUPIXENT Pre-filled Syringe – Pediatric Atopic Dermatitis (6 mo-5 yr) Product Overview
DUPIXENT Pre-filled Syringe – Pediatrics (6-11 years)
DUPIXENT Pre-filled Syringe – Pediatrics (6-11 years) Product Overview
Injectable Drug Delivery Device
Injectable Drug Delivery Device Product Overview
Regeneron Pharmaceuticals Inc – Key Competitors
Regeneron Pharmaceuticals Inc – Key Employees
Regeneron Pharmaceuticals Inc – Key Employee Biographies
Regeneron Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Regeneron Pharmaceuticals Inc, Recent Developments
Sep 05, 2020: Kaskela Law announces investigation of Regeneron Pharmaceuticals (Regn) and encourages long-term Regn stockholders to contact the firm
Jun 24, 2020: Kymab wins Supreme Court case against Regeneron
Jun 03, 2020: Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents
Apr 14, 2020: Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron
Feb 08, 2020: EYLEA (aflibercept) injection reduced risk of developing vision-threatening events by 75% after two years in patients with diabetic retinopathy
Feb 06, 2020: Regeneron reports fourth quarter and full year 2019 financial and operating results
Jan 23, 2020: Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea
Jan 08, 2020: Publication highlights Regeneron’s costimulatory bispecific antibodies, an emerging class of cancer immunotherapy
Dec 12, 2019: Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education
Nov 22, 2019: Regeneron’s Yancopoulos receives Columbia College’s Alexander Hamilton Award
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Regeneron Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview
Regeneron Pharmaceuticals Inc Pipeline Products by Equipment Type
Regeneron Pharmaceuticals Inc Pipeline Products by Indication
Regeneron Pharmaceuticals Inc, Key Facts
Regeneron Pharmaceuticals Inc, Major Products and Services
Regeneron Pharmaceuticals Inc Number of Pipeline Products by Development Stage
Regeneron Pharmaceuticals Inc Pipeline Products Summary by Development Stage
DUPIXENT Pre-filled Syringe - Product Status
DUPIXENT Pre-filled Syringe - Product Description
DUPIXENT Pre-filled Syringe - Adolescents - Product Status
DUPIXENT Pre-filled Syringe - Adolescents - Product Description
DUPIXENT Pre-filled Syringe - Pediatric Atopic Dermatitis (6 mo-5 yr) - Product Status
DUPIXENT Pre-filled Syringe - Pediatric Atopic Dermatitis (6 mo-5 yr) - Product Description
DUPIXENT Pre-filled Syringe - Pediatrics (6-11 years) - Product Status
DUPIXENT Pre-filled Syringe - Pediatrics (6-11 years) - Product Description
Injectable Drug Delivery Device - Product Status
Injectable Drug Delivery Device - Product Description
Regeneron Pharmaceuticals Inc, Key Employees
Regeneron Pharmaceuticals Inc, Key Employee Biographies
Regeneron Pharmaceuticals Inc, Other Locations
Regeneron Pharmaceuticals Inc, Subsidiaries
Glossary